

Connecting via Winsock to STN at stnc.cas.org on port 23

Welcome to STN International! Enter x:X

LOGINID:ssspta1805sxm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS	3	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS	4	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS	5	DEC 18	ReaxysFile available on STN
NEWS	6	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS	7	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in CAplus
NEWS	8	JAN 24	The new and enhanced DPCI file on STN has been released
NEWS	9	JAN 26	Improved Timeliness of CAS Indexing Adds Value to USPATFULL and USPAT2 Chemistry Patents
NEWS	10	JAN 26	Updated MeSH vocabulary, new structured abstracts, and other enhancements improve searching in STN reload of MEDLINE
NEWS	11	JAN 28	CABA will be updated weekly
NEWS	12	FEB 23	PCTFULL file on STN completely reloaded
NEWS	13	FEB 23	STN AnaVist Test Projects Now Available for Qualified Customers
NEWS	14	FEB 25	LPCI will be replaced by LDPCI
NEWS	15	MAR 07	Pricing for SELECTing Patent, Application, and Priority Numbers in the USPAT and IFI Database Families is Now Consistent with Similar Patent Databases on STN
NEWS	16	APR 26	Expanded Swedish Patent Application Coverage in CA/CAplus Provides More Current and Complete Information
NEWS	17	APR 28	The DWPI (files WPINDEX, WPIDS and WPIX) on STN have been enhanced with thesauri for the European Patent Classifications
NEWS	18	MAY 02	MEDLINE Improvements Provide Fast and Simple Access to DOI and Chemical Name Information
NEWS	19	MAY 12	European Patent Classification thesauri added to the INPADOC files, PCTFULL, GBFULL and FRFULL
NEWS	20	MAY 23	Enhanced performance of STN biosequence searches
NEWS	21	MAY 23	Free Trial of the Numeric Property Search Feature in PCTFULL on STN
NEWS	22	JUN 20	STN on the Web Enhanced with New Patent Family Assistant and Updated Structure Plug-In
NEWS	23	JUN 20	INPADOC databases enhanced with first page images
NEWS	24	JUN 20	PATDPA database updates to end in June 2011
NEWS	25	JUN 21	INPADOC: Delay of German patent coverage

NEWS EXPRESS 17 DECEMBER 2010 CURRENT WINDOWS VERSION IS V8.4.2 .1,
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:25:04 ON 21 JUN 2011

=> file medline caplus embase biotechno scisearch biosis		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.23	0.23

FILE 'MEDLINE' ENTERED AT 12:25:42 ON 21 JUN 2011

FILE 'CAPLUS' ENTERED AT 12:25:42 ON 21 JUN 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:25:42 ON 21 JUN 2011
Copyright (c) 2011 Elsevier B.V. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 12:25:42 ON 21 JUN 2011
COPYRIGHT (C) 2011 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 12:25:42 ON 21 JUN 2011
Copyright (c) 2011 The Thomson Corporation

FILE 'BIOSIS' ENTERED AT 12:25:42 ON 21 JUN 2011
Copyright (c) 2011 The Thomson Corporation

=> s flt3 or flt-3
L1 21462 FLT3 OR FLT-3

=> s l1 and antisense
L2 187 L1 AND ANTISENSE

=> s l1 and sirna
L3 179 L1 AND SIRNA

=> s l1 and ribozyme
L4 10 L1 AND RIBOZYME

=> s l1 and rnai
L5 49 L1 AND RNAI

=> s l5 or l3
L6 209 L5 OR L3

=> s l2 not (sirna or rnai)
L7 149 L2 NOT (SIRNA OR RNAI)

=> dup rem l4

PROCESSING COMPLETED FOR L4

L8 8 DUP REM L4 (2 DUPLICATES REMOVED)

=> dup rem 16

PROCESSING COMPLETED FOR L6

L9 145 DUP REM L6 (64 DUPLICATES REMOVED)

=> dup rem 17

PROCESSING COMPLETED FOR L7

L10 92 DUP REM L7 (57 DUPLICATES REMOVED)

=> d 1-8 ti 18

L8 ANSWER 1 OF 8 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

TI Survivin: A target from brain cancer to neurodegenerative disease.

L8 ANSWER 2 OF 8 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

TI Genetic therapies against HIV.

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN

TI Expansion of renewable stem cell populations using modulators of phosphatidylinositol 3-kinase, and therapeutic applications

L8 ANSWER 4 OF 8 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

TI Hematopoietic stem cell-based gene therapy against HIV infection: Promises and caveats.

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN

TI Trans-splicing ribozyme mediated preparation of biopharmaceutical and protein for therapeutic and diagnostic applications

L8 ANSWER 6 OF 8 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

DUPLICATE 1

TI Gene therapy for inborn and acquired immune deficiency disorders.

L8 ANSWER 7 OF 8 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

DUPLICATE 2

TI Current status of retroviral vector mediated gene transfer into human hematopoietic stem cells.

L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2011 ACS on STN

TI Studies on expression of hematopoietic growth factors regulated by Eg-1 promoter

=> s 19 and (cancer or leukemia or aml)

L11 109 L9 AND (CANCER OR LEUKEMIA OR AML)

=> d ti 1-109

L11 ANSWER 1 OF 109 MEDLINE on STN

TI Molecular characterization and prognostic significance of FLT3 in CML progression.

L11 ANSWER 2 OF 109 MEDLINE on STN

TI ITD- and FL-induced FLT3 signal transduction leads to increased C/EBPbeta-LIP expression and LIP/LAP ratio by different signalling modules.

L11 ANSWER 3 OF 109 MEDLINE on STN
 TI Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia.

L11 ANSWER 4 OF 109 MEDLINE on STN
 TI Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.

L11 ANSWER 5 OF 109 MEDLINE on STN
 TI FLT3 regulates beta-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells.

L11 ANSWER 6 OF 109 MEDLINE on STN
 TI Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51.

L11 ANSWER 7 OF 109 MEDLINE on STN
 TI Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.

L11 ANSWER 8 OF 109 MEDLINE on STN
 TI DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.

L11 ANSWER 9 OF 109 MEDLINE on STN
 TI Constitutively activated FLT3 phosphorylates BAD partially through pim-1.

L11 ANSWER 10 OF 109 MEDLINE on STN
 TI Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.

L11 ANSWER 11 OF 109 MEDLINE on STN
 TI Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.

L11 ANSWER 12 OF 109 MEDLINE on STN
 TI Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.

L11 ANSWER 13 OF 109 MEDLINE on STN
 TI Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

L11 ANSWER 14 OF 109 MEDLINE on STN
 TI RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.

L11 ANSWER 15 OF 109 MEDLINE on STN
 TI FLT3/ITD mutation signaling includes suppression of SHP-1.

L11 ANSWER 16 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Delivery of interference RNA using dock-and-lock complexes of antibodies fused with anchoring domains and dimerization-and-docking domains

L11 ANSWER 17 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Suicide ready genetically modified cells and cytotoxic agents that induce

apoptosis in the cells to provide cell-based therapy

- L11 ANSWER 18 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Class I anti-CEA antibodies for cancer therapy
- L11 ANSWER 19 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI siRNA oligonucleotides inhibiting cellular migration targeted to thrombospondin-1 and other related proteins and use thereof for the prevention or the treatment of invasive or metastatic tumors
- L11 ANSWER 20 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Oligonucleotides inhibiting cellular migration via thrombospondin-1 expression and useful for the prevention or treatment of primary, invasive, or metastatic tumors
- L11 ANSWER 21 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Bispecific immunocytokine dock-and-lock (DNL) complexes for therapy
- L11 ANSWER 22 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy
- L11 ANSWER 23 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Anti-CD74 immunoconjugates and methods of use in targeted diagnosis and therapy
- L11 ANSWER 24 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Anti-CD74 immunoconjugates and methods of use in targeted diagnosis and therapy
- L11 ANSWER 25 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Bruton's tyrosine kinase as anti-cancer drug target
- L11 ANSWER 26 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Dendritic cell-targeting antibodies linked to xenoantigen moieties as vaccine complex against cancer
- L11 ANSWER 27 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Transcription factors and regulatory proteins associated with pluripotency and their use as targets in induction of pluripotent stem cell formation
- L11 ANSWER 28 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Epidermal growth factor receptor/NEDD9/transforming growth factor- β interactome and its use for identification of agents to treat hyperproliferative disorders
- L11 ANSWER 29 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type 1 receptor (IGF-1R)
- L11 ANSWER 30 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Humanized anti-HLA-DR antibodies
- L11 ANSWER 31 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Novel strategies for improved cancer vaccines
- L11 ANSWER 32 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Preparation of purine derivatives that expand hematopoietic stem cells
- L11 ANSWER 33 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Molecular vaccines for infectious disease

L11 ANSWER 34 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Chimeric vaccines comprising dendritic cell-binding, dimerization and docking, anchor domain and xenoantigen moieties for cancer therapy

L11 ANSWER 35 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Anti-pancreatic cancer antibodies with high specificity to pancreatic cancers and their uses in pancreas tumor diagnosis and treatment

L11 ANSWER 36 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Methods for diagnosis, prognosis and treatment

L11 ANSWER 37 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Identifying aberrant tyrosine kinases in patients with hematological malignancies using siRNAs, electroporation and MTS assay, and use of identified kinases as drug targets

L11 ANSWER 38 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Anti-pancreatic cancer antibodies

L11 ANSWER 39 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas

L11 ANSWER 40 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI An animal host system for instigation of growth or metastasis of implanted indolent tumors

L11 ANSWER 41 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells

L11 ANSWER 42 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

L11 ANSWER 43 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Protein kinases catalyzing phosphorylation of α -synuclein as targets for the treatment of Lewy body diseases

L11 ANSWER 44 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Receptor tyrosine kinase profiling

L11 ANSWER 45 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Efficacy of RNAi-induced down-regulation of wild-type FLT3 on NF- κ B pathway in THP-1 cell line

L11 ANSWER 46 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Flt3 receptor inhibition reduces constitutive NF κ B activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

L11 ANSWER 47 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Effect of FLT3-targeted RNAi on myeloproliferation in THP-1 cells and probable mechanisms

L11 ANSWER 48 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Use of agonists of death receptors in the induction of apoptosis in cancer cells

L11 ANSWER 49 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Sulfonamide derivatives as modulators of multiple kinases and their

preparation

- L11 ANSWER 50 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Methods of using combinations of siRNA for treating a disease or a disorder, and for enhancing siRNA efficacy in RNAi
- L11 ANSWER 51 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Allogeneic stem cell transplants in non-conditioned recipients
- L11 ANSWER 52 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Pharmaceutical combinations of staurosporines with antisense oligonucleotides or mcl-1-specific RNAi constructs, for treatment of myelodysplastic syndromes, lymphomas, leukemias, and solid tumors
- L11 ANSWER 53 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Screening the inhibitor of binding of activated mutant FLT3 and Lyn and there use for treatment of acute myeloid leukemia
- L11 ANSWER 54 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Treatment of disc degenerative disease using cells able to increase angiogenesis alone or in combination with growth factors or a matrix and compositions for same
- L11 ANSWER 55 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
- L11 ANSWER 56 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Identification of TSC-22 as a potential tumor suppressor that is upregulated by Flt3-D835V but not Flt3-ITD
- L11 ANSWER 57 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Apoptotic cell-responding B220- dendritic cell for identifying immunomodulator against autoimmune disease, transplant rejection, infection and cancer
- L11 ANSWER 58 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Transdermal delivery of pharmaceutical agent comprising genetic molecule
- L11 ANSWER 59 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Transcatheter tumor immunoembolization
- L11 ANSWER 60 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Methods and compositions for generating bioactive assemblies of increased complexity and their therapeutic and diagnostic uses
- L11 ANSWER 61 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Transgenic zebrafish model comprising Ras or other mammalian oncogene and its use in screening for antitumor agents or modulators of sensitivity to chemotherapy or radiation therapy
- L11 ANSWER 62 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Stably tethered structures of defined composition with multiple functions or binding specificities for disease diagnosis and treatment
- L11 ANSWER 63 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers
- L11 ANSWER 64 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
TI Interference with interleukin-10 enhances the Th1 response in connection with dendritic cell vaccines

L11 ANSWER 65 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI RNAi-induced down-regulation of FLT3 expression causes growth inhibition and apoptosis and increases in combination with kinase inhibitor

L11 ANSWER 66 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Combination of mTOR inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

L11 ANSWER 67 OF 109 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Cytokines and retinoic acid receptor antagonists for expansion of renewable stem cells and adoptive immunotherapy

L11 ANSWER 68 OF 109 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells.

L11 ANSWER 69 OF 109 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set.

L11 ANSWER 70 OF 109 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI RNA-mediated gene silencing in hematopoietic cells.

L11 ANSWER 71 OF 109 SCISEARCH COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI t(4;11) leukemias display addiction to MLL-AF4 but not to AF4-MLL

L11 ANSWER 72 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI DOWNSTREAM EFFECTORS OF FIP1L1-PDGFR α AS TARGETS FOR THERAPY IN CHRONIC EOSINOPHILIC LEUKEMIA.

L11 ANSWER 73 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

L11 ANSWER 74 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1.

L11 ANSWER 75 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI MYB Overexpression Is Directly Involved in Acute Myeloid Leukemia Pathogenesis and Could Constitute a New Therapeutic Target for Patients with Aberrant Expression of This Gene.

L11 ANSWER 76 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia.

L11 ANSWER 77 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Impaired S Phase Arrest in AML Cells with a FLT3-ITD Treated with

Clofarabine Allows Prolonged Drug exposure to Reverse the Chemoresistant Phenotype.

- L11 ANSWER 78 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI Regulation of ABCB1 (p-glycoprotein) by the FOXO1 Transcription Factor in Acute Myeloid Leukemia.
- L11 ANSWER 79 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI SRC Is a Critical Signaling Mediator in FLT3-ITD Positive AML.
- L11 ANSWER 80 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI STUDYING THE ROLE OF PIM KINASES IN FLT3-ITD-INDUCED LEUKEMIA REVEALED PIM1 AS REGULATOR OF CXCL12/CXCR4-MEDIATED HOMING AND MIGRATION.
- L11 ANSWER 81 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI Inhibition of mitogen-activated protein kinase 1 sensitizes pancreatic cancer cells to the treatment with erlotinib.
- L11 ANSWER 82 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI Using RNAi-based high-throughput screen to identify novel signaling pathways regulating oral cancer cells proliferation.
- L11 ANSWER 83 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI Dissecting Proto-Oncogenic PIM Serine/Threonine Kinases in FLT3-ITD-Induced Leukemogenesis: PIM1 Regulates CXCL12/CXCR4-Mediated Homing and Migration.
- L11 ANSWER 84 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI Collaboration of the Meningioma 1 (MN1) Oncogene with MLL-Fusions in Pediatric Leukemia.
- L11 ANSWER 85 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI MMP-14 Mediates Migration of Acute Myelogenous Leukemia Cells.
- L11 ANSWER 86 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI A Molecular Signature for a Cytokine Receptor Survival Pathway in AML Identifies Unique Prognostic Indicators and Therapeutic Targets.
- L11 ANSWER 87 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI Autocrine IGF-1/IGF-1R Signaling Is Responsible for PI3K/Akt Constitutive Activation in Acute Myeloid Leukemia.
- L11 ANSWER 88 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients.
- L11 ANSWER 89 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
TI The Role of Mcl-1 Expression and Phosphorylation in Resistance to Chemotherapy and Kinase Inhibitors in FLT3-ITD-Positive Acute Myeloid Leukemia (AML).

L11 ANSWER 90 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI FLT3 INTERNAL TANDEM DUPLICATION INVOLVING ITS LIBIQUITIN DEPENDENT ENDOCYTOSIS MOTIF SUSPEND MODULATION BY HDM2 AND ARE ASSOCIATED WITH INFERIOR SURVIVAL IN AML.

L11 ANSWER 91 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation.

L11 ANSWER 92 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Innate immune factors are expressed among peripheral blood CD34(+) HSCs, are induced upon exposure to lentiviral vectors and may limit transduction efficiency.

L11 ANSWER 93 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Identification of tyrosine residues of importance for survival signaling through the scaffolding protein Gab2 in both wild-type FLT3 and the FLT3-ITD.

L11 ANSWER 94 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI RNAi functional screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia patients.

L11 ANSWER 95 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Internal tandem duplications of FLT3 induces increased ROS production, DNA damage and misrepair: Implications for genomic instability and disease resistance in myeloid malignancies.

L11 ANSWER 96 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI MEIS1 is a required transcription factor for AML cell proliferation.

L11 ANSWER 97 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.

L11 ANSWER 98 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Targeting mutant nucleophosmin (NPM) 1: A promising approach to induce growth inhibition and differentiation in human AML.

L11 ANSWER 99 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Mesenchymal cells determine the response of acute lymphoblastic leukemia cells to L-asparaginase.

L11 ANSWER 100 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Inhibition of histone deacetylase (HDAC) 6 and/or heat shock protein (HSP) 90: A strategy to abrogate multi-level protective responses to misfolded proteins induced by proteasome inhibitors in human leukemia cells.

L11 ANSWER 101 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on

STN

- TI Knockdown of the nuclear oncogene SKI inhibits Flt3-ITD induced signaling in 32D-Flt3-ITD cells.
- L11 ANSWER 102 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
- TI The role of expression of FLICE and FLICE-inhibitory protein isoforms in acute myeloid leukemia.
- L11 ANSWER 103 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
- TI The Hsp90 inhibitor, 17-AAG, and topoisomerase II inhibitor, etoposide, synergistically inhibit leukemias with FLT3 mutations through inhibition of DNA repair proteins, Chk1 and Rad51.
- L11 ANSWER 104 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
- TI In AML, Cbl serves as nexus for signaling from Flt3, and is required for coupling JNK1 in a pathway of survival and proliferation involving c-jun/AP-1.
- L11 ANSWER 105 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
- TI Depletion of NUP98: A common leukemogenetic mechanism in AML?.
- L11 ANSWER 106 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
- TI The dual SRC/ABL kinase inhibitor BMS-354825 potently inhibits the growth of myeloid leukemic cells characterized by Flt3-ITD expression, GM-CSF dependency, or G-CSF responsiveness via an ABL-independent mechanism.
- L11 ANSWER 107 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
- TI A potent Src/Abl kinase inhibitor (AP23464) potently inhibits the growth of myeloid leukemic cells characterized by Flt3-ITD expression, GM-CSF dependency, or GM-CSF responsiveness via an Abl-independent mechanism.
- L11 ANSWER 108 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
- TI The Hsp90 inhibitor 17-AAG and FLT3 kinase inhibitor GTP14564 synergistically inhibit MLL fusion gene leukemias with FLT3 mutations.
- L11 ANSWER 109 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
- TI Differentially regulated signaling pathways in monosomy 7 and 7q- AML.

=> d 94

- L11 ANSWER 94 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
- AN 2008:215439 BIOSIS
- DN PREV200800215481
- TI RNAi functional screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia patients.
- AU Tyner, Jeffrey W. [Reprint Author]; Willis, Stephanie; Deininger, Michael W. N.; Druker, Brian J.
- CS Oregon Hlth and Sci Univ, Inst Canc, Portland, OR USA
- SO Blood, (NOV 16 2007) Vol. 110, No. 11, Part 1, pp. 69A.
Meeting Info.: 49th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA, USA. December 08 -11, 2007. Amer Soc Hematol.
CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Mar 2008
Last Updated on STN: 26 Mar 2008

=> d 88

L11 ANSWER 88 OF 109 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on
STN
AN 2009:257460 BIOSIS
DN PREV200900257460
TI RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in
Leukemia Patients.
AU Tyner, Jeffrey W. [Reprint Author]; Loriaux, Marc; Willis, Stephanie G.;
Chang, Bill; Bicocca, Vincent T.; Oh, Stephen; Hollink, Iris H. I. M.;
Segers, Stefanie; den Boer, Monique L.; Zwaan, C. M.; Gotlib, Jason R.;
Deininger, Michael W. N.; Druker, Brian J.
CS Oregon Hlth and Sci Univ, Inst Canc, Portland, OR 97201 USA
SO Blood, (NOV 16 2008) Vol. 112, No. 11, pp. 281.
Meeting Info.: 50th Annual Meeting of the American- Society-of-Hematology.
San Francisco, CA, USA. December 06 -09, 2008. Amer Soc Hematol.
CODEN: BLOOAW. ISSN: 0006-4971.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 16 Apr 2009
Last Updated on STN: 16 Apr 2009

=> d his

(FILE 'HOME' ENTERED AT 12:25:04 ON 21 JUN 2011)

FILE 'MEDLINE, CAPLUS, EMBASE, BIOTECHNO, SCISEARCH, BIOSIS' ENTERED AT
12:25:42 ON 21 JUN 2011

L1 21462 S FLT3 OR FLT-3
L2 187 S L1 AND ANTISENSE
L3 179 S L1 AND SIRNA
L4 10 S L1 AND RIBOZYME
L5 49 S L1 AND RNAI
L6 209 S L5 OR L3
L7 149 S L2 NOT (SIRNA OR RNAI)
L8 8 DUP REM L4 (2 DUPLICATES REMOVED)
L9 145 DUP REM L6 (64 DUPLICATES REMOVED)
L10 92 DUP REM L7 (57 DUPLICATES REMOVED)
L11 109 S L9 AND (CANCER OR LEUKEMIA OR AML)

=> d 1-92 ti 110

L10 ANSWER 1 OF 92 MEDLINE on STN
TI Expression of ARC (apoptosis repressor with caspase recruitment domain),
an antiapoptotic protein, is strongly prognostic in AML.

L10 ANSWER 2 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Cell therapy product for the treatment of HIV infection

L10 ANSWER 3 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Engineered cells expressing multiple immunomodulators and uses thereof

L10 ANSWER 4 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN

TI TNIK inhibitor and the use
 L10 ANSWER 5 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Identification of novel methylation markers in hepatocellular carcinoma using a methylation array
 L10 ANSWER 6 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI Survivin: A target from brain cancer to neurodegenerative disease.
 L10 ANSWER 7 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI 10 Years CESAR anticancer drug research - The 7th CESAR annual meeting 2009.
 L10 ANSWER 8 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Predicting response to chemotherapy and EGFR inhibition by determining expression of ligand of VEGF or/and receptor of VEGFR families, wherein ligand up-regulation predicts therapy success
 L10 ANSWER 9 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Predicting response to chemotherapy and EGFR inhibition by determining expression of ligand of VEGF or/and receptor of VEGFR families, wherein ligand up-regulation predicts therapy success
 L10 ANSWER 10 OF 92 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Selective inhibition of STAT5 expression in acute myeloid leukemia cells results in potent antitumor activity.
 L10 ANSWER 11 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Methods and compositions for treating cancer using Bcl-2 antisense oligomers, tyrosine kinase inhibitors, and chemotherapeutic agents
 L10 ANSWER 12 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Methods and compositions for treating cancer using Bcl-2 antisense oligomers, tyrosine kinase inhibitors, and chemotherapeutic agents
 L10 ANSWER 13 OF 92 MEDLINE on STN
 TI Systemic cancer therapy: evolution over the last 60 years.
 L10 ANSWER 14 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI BRAF kinase in melanoma development and progression.
 L10 ANSWER 15 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
 L10 ANSWER 16 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI New biological approaches in asthma: DNA-based therapy.
 L10 ANSWER 17 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI Genetic therapies against HIV.
 L10 ANSWER 18 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI Electroporation-mediated gene therapy.
 L10 ANSWER 19 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights

reserved on STN

TI Potential target molecules for Ex Vivo expansion of hematopoietic stem cells and their roles in normal hematopoiesis.

L10 ANSWER 20 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

TI Potential utilization of bystander/abscopal-mediated signal transduction events in the treatment of solid tumors.

L10 ANSWER 21 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN

TI Genes showing altered levels of expression in cancers as targets for cancer therapy

L10 ANSWER 22 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN

TI Nucleophosmin (NPM) protein mutants, NPM polynucleotide sequences and their diagnostic, prognostic and therapeutic uses for acute myeloid leukemia

L10 ANSWER 23 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN

TI Flt3 inhibitors for immune suppression

L10 ANSWER 24 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN

TI Use of K-252a and kinase inhibitors for the prevention or treatment of HMGB1-associated pathologies

L10 ANSWER 25 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN

TI Expansion and inhibition of differentiation of stem/progenitor cells for therapeutic use by inhibiting Sir2 deacetylase

L10 ANSWER 26 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

TI Potential gene therapy strategies for cancer stem cells.

L10 ANSWER 27 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

TI Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway.

L10 ANSWER 28 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

TI Cancer and kinases: Reports from the front line.

L10 ANSWER 29 OF 92 SCISEARCH COPYRIGHT (c) 2011 The Thomson Corporation on STN

TI New agents for the treatment of acute myeloid leukemia

L10 ANSWER 30 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

TI The ABCs of targeting Raf: Novel approaches to cancer therapy.

L10 ANSWER 31 OF 92 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN

TI 1st Scientific Meeting of Canceropole-Lyon-Auvergne-Rhone-Alpes, Clermont Ferrand, FRANCE, March 16 -17, 2006.

L10 ANSWER 32 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN

TI Combination composition comprising an antagonist of tissue factor (TF) and an anticancer compound for treating disorders related to TF dysfunction

L10 ANSWER 33 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN

TI Pharmaceutical composition comprised of TGF- β antagonist and anti-neoplastic chemotherapeutic agent, and its use in treatment of

various cancers

- L10 ANSWER 34 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Hyperthermic inducible mammalian expression vectors containing the HSP70B promoter and use thereof, including for interleukin 2 expression, cancer therapy, and immunotherapy
- L10 ANSWER 35 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Methods for detection of gene amplification or deletion associated with cancer and methods of inhibition of cancer
- L10 ANSWER 36 OF 92 MEDLINE on STN DUPLICATE 1
TI Raf kinase as a target for anticancer therapeutics.
- L10 ANSWER 37 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
TI Nonviral vectors for cancer gene therapy: Prospects for integrating vectors and combination therapies.
- L10 ANSWER 38 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
TI Gene therapy for malignant glioma: Current clinical status.
- L10 ANSWER 39 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
TI Targeted therapy for hematologic malignancies.
- L10 ANSWER 40 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Alternative reading frame peptides as antigens for the prophylaxis and treatment of cancer and infectious diseases
- L10 ANSWER 41 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Expansion of renewable stem cell populations using modulators of PI 3-kinase
- L10 ANSWER 42 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Reporter genes under control of regulated promoters and their use in imaging of transgenic animal cells
- L10 ANSWER 43 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Cell modulation using a cytoskeletal protein
- L10 ANSWER 44 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Autogene nucleic acids encoding a secretable RNA polymerase, lipid-autogene complexes, and uses for gene therapy
- L10 ANSWER 45 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Oncogene transgenic fish as mammalian cancer model, and uses for anticancer drug screening
- L10 ANSWER 46 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
TI Expansion of hematopoietic stem cells using thrombopoietin agonist and TGF- β blocking agent, and therapeutic applications
- L10 ANSWER 47 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
TI Regulation of hematopoietic stem cell growth.
- L10 ANSWER 48 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
TI [Targeted therapies in neoplastic disorders of hematopoietic system].
Terapia celowana w nowotworach układu hematopoetycznego.

L10 ANSWER 49 OF 92 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on STN
 TI Oncogenic tyrosine kinases regulate proliferative and survival signals through activation of Id1.

L10 ANSWER 50 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI Targeted Molecules in Small Cell Lung Cancer.

L10 ANSWER 51 OF 92 MEDLINE on STN DUPLICATE 2
 TI Acute myeloid leukemia.

L10 ANSWER 52 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN
 TI Preface.

L10 ANSWER 53 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Methods for treating cancer

L10 ANSWER 54 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Inducible expression of therapeutic polypeptides under control of heat shock promoter for gene therapy

L10 ANSWER 55 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Colloidal metal compositions and methods for treatment of cancer

L10 ANSWER 56 OF 92 MEDLINE on STN DUPLICATE 3
 TI Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia.

L10 ANSWER 57 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Induction and post-remission therapy: new agents

L10 ANSWER 58 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Cytokine gene expression in human bone marrow stromal cells: quantitative analysis with real-time polymerase chain reaction

L10 ANSWER 59 OF 92 MEDLINE on STN DUPLICATE 4
 TI Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies.

L10 ANSWER 60 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Autogene nucleic acids encoding secretable RNA polymerase, lipid-autogene complexes, and their use for therapeutic gene expression and disease treatment

L10 ANSWER 61 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Gene expression profiles in bone and cartilage formation and their use in diagnosis and treatment of disease

L10 ANSWER 62 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Transforming growth factor beta (TGF- β) blocking agent-treated stem cell composition and method

L10 ANSWER 63 OF 92 MEDLINE on STN DUPLICATE 5
 TI The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34(+) cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells.

L10 ANSWER 64 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN

TI Mucosal Immunology - 11th International Congress: 16-20 June 2002,
 Orlando, FL, USA.

L10 ANSWER 65 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights
 reserved on STN DUPLICATE 6
 TI Therapy of secondary leukemia.

L10 ANSWER 66 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights
 reserved on STN DUPLICATE 7
 TI Receptor tyrosine kinase mutations in myeloid neoplasms.

L10 ANSWER 67 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights
 reserved on STN DUPLICATE 8
 TI Update on hematopoietic stem cell gene transfer using non-human primate
 models.

L10 ANSWER 68 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI TWEAK receptor modulators for treating diseases mediated by angiogenesis

L10 ANSWER 69 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Protein and cDNA sequences of human EPO primary response gene 1 (EPRG1)
 and its diagnostic and therapeutic uses

L10 ANSWER 70 OF 92 MEDLINE on STN DUPLICATE 9
 TI Flt-3 and its ligand are expressed in neural crest-derived tumors and
 promote survival and proliferation of their cell lines.

L10 ANSWER 71 OF 92 MEDLINE on STN DUPLICATE 10
 TI Stem cell growth factor: in situ hybridization analysis on the gene
 expression, molecular characterization and in vitro proliferative activity
 of a recombinant preparation on primitive hematopoietic progenitor cells.

L10 ANSWER 72 OF 92 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on
 STN
 TI Genes and pathways associated with induction of apoptosis in primitive AML
 cells.

L10 ANSWER 73 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights
 reserved on STN DUPLICATE 11
 TI Differentiation induction of dendritic cell phenotypes from human leukemic
 cell lines.

L10 ANSWER 74 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Methods of immunosuppression

L10 ANSWER 75 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Eukaryotic layered vector initiation systems (ELVIS) comprising alphavirus
 and especially Sindbis virus vectors for recombinant expression of
 heterologous protein genes

L10 ANSWER 76 OF 92 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on
 STN
 TI Ex vivo expansion of primitive hematopoietic cells by reduction of
 p21cip1/waf1 expression level.

L10 ANSWER 77 OF 92 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on
 STN
 TI Ontogeny-associated changes in the apoptotic regulation of primitive human
 hematopoietic cells.

L10 ANSWER 78 OF 92 BIOSIS COPYRIGHT (c) 2011 The Thomson Corporation on
 STN

TI Cloning and characterization of a novel cytokine-inducible protein(P29).
 L10 ANSWER 79 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
 L10 ANSWER 80 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Methods and compositions for enhancing immune response and for the production of in vitro MABs
 L10 ANSWER 81 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Mammalian expression constructs inducible by hyperthermia for use in gene therapy
 L10 ANSWER 82 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Genes, vectors and cells encoding ligand-binding chimeric proteins which may be oligomerized with multimeric synthetic ligands to induce a biochemical activity
 L10 ANSWER 83 OF 92 MEDLINE on STN DUPLICATE 12
 TI Involvement of the retinoblastoma protein in monocytic and neutrophilic lineage commitment of human bone marrow progenitor cells.
 L10 ANSWER 84 OF 92 EMBASE COPYRIGHT (c) 2011 Elsevier B.V. All rights reserved on STN DUPLICATE 13
 TI Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis.
 L10 ANSWER 85 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Improving the efficiency of gene transfer into animal cells by synchronizing a prestimulated population with cell cycle inhibitors and transformation after release of the block
 L10 ANSWER 86 OF 92 MEDLINE on STN DUPLICATE 14
 TI The transcription factors c-myb and GATA-2 act independently in the regulation of normal hematopoiesis.
 L10 ANSWER 87 OF 92 MEDLINE on STN DUPLICATE 15
 TI Induction of hematopoietic commitment and erythromyeloid differentiation in embryonal stem cells constitutively expressing c-myb.
 L10 ANSWER 88 OF 92 MEDLINE on STN DUPLICATE 16
 TI Accelerated cell-cycling of hematopoietic progenitors by the flt3 ligand that is modulated by transforming growth factor-beta.
 L10 ANSWER 89 OF 92 MEDLINE on STN DUPLICATE 17
 TI FLT3/FLK-2 (STK-1) Ligand does not stimulate human megakaryopoiesis in vitro.
 L10 ANSWER 90 OF 92 MEDLINE on STN
 TI Expression and physiologic significance of Kit ligand and stem cell tyrosine kinase-1 receptor ligand in normal human CD34+, c-Kit+ marrow cells.
 L10 ANSWER 91 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Antisense molecules directed against a platelet-derived growth factor receptor-related gene
 L10 ANSWER 92 OF 92 MEDLINE on STN DUPLICATE 18
 TI STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of

early progenitor/stem cells.

=> d 110 11 23 91

L10 ANSWER 11 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2008:583352 CAPLUS
DN 148:529452
TI Methods and compositions for treating cancer using Bcl-2 antisense
oligomers, tyrosine kinase inhibitors, and chemotherapeutic agents
IN Brown, Bob D.
PA Genta Inc., USA
SO PCT Int. Appl., 22 pp., which
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008058225	A2	20080515	WO 2007-US84014	20071108
	WO 2008058225	A3	20080904		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	US 20080171718	A1	20080717	US 2007-935654	20071106
PRAI	US 2006-864859P	P	20061108		
	US 2007-935654	A	20071106		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L10 ANSWER 23 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2006:167710 CAPLUS
DN 144:267266
TI Flt3 inhibitors for immune suppression
IN Small, Donald; Whartenby, Katherine A.; Pardoll, Drew
PA The Johns Hopkins University, USA
SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006020145	A2	20060223	WO 2005-US25318	20050714
	WO 2006020145	A3	20070308		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

AU 2005274852 A1 20060223 AU 2005-274852 20050714
 CA 2574150 A1 20060223 CA 2005-2574150 20050714
 EP 1778224 A2 20070502 EP 2005-790718 20050714

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, YU

CN 101022799 A 20070822 CN 2005-80031410 20050714
 JP 2008506778 T 20080306 JP 2007-522605 20050714
 IN 2007KN00583 A 20070706 IN 2007-KN583 20070216
 US 20090054358 A1 20090226 US 2008-632924 20081016

PRAI US 2004-589511P P 20040719
 WO 2005-US25318 W 20050714

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 144:267266

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 91 OF 92 CAPLUS COPYRIGHT 2011 ACS on STN

AN 1994:692766 CAPLUS

DN 121:292766

OREF 121:53295a,53298a

TI Antisense molecules directed against a platelet-derived growth factor
 receptor-related gene

IN Denner, Larry A.; Rege, Ajay A.; Dixon, Richard A. F.

PA Texas Biotechnology Corp., USA

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9415943	A1	19940721	WO 1993-US12602	19931228
	W: AU, CA, CZ, HU, JP, KR, PL, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9459610	A	19940815	AU 1994-59610	19931228
PRAI	US 1992-999708	A	19921231		
	WO 1993-US12602	W	19931228		

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

118.40

118.63

STN INTERNATIONAL LOGOFF AT 12:43:13 ON 21 JUN 2011